Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 12:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 1,709 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Human Immunodeficiency Virus Infection (HIV) Clear all

Conditions: HIV-1
Interventions: F/TAF, 3rd ARV agent, Boosted PIs; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 4
States / cities: Los Angeles, California • Aurora, Colorado • Philadelphia, Pennsylvania + 1 more

Conditions: HIV Infections, HIV Seronegativity
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 24 Hours to 21 Years
Enrollment: 4,150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2002
U.S. locations: 89
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 52 more

Conditions: HIV Infections, Histoplasmosis
Interventions: Itraconazole; Drug
Lead sponsor: Janssen, LP; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 7
States / cities: Indianapolis, Indiana • Kansas City, Missouri • Memphis, Tennessee + 1 more

Conditions: Kaposi Sarcoma, HIV Infection
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Human Immunodeficiency Virus
Interventions: Intervention Arm (computer-based CARE+ Corrections tool), Educational video on opiate overdose prevention; Device · Other
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Human Immunodeficiency Virus (HIV), Mitochondrial Diseases
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases, Cardiovascular Abnormalities, Abnormality of Adipose Tissue, Body Weight Changes, Body Fat Disorder, HIV-Associated Lipodystrophy Syndrome
Interventions: Dolutegravir 50 MG, Antiretroviral/Anti HIV; Drug
Lead sponsor: Augusta University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: HIV Infections
Interventions: EVG, RTV, ARV regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: Not listed
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 47
States / cities: Pheonix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 44 more

Conditions: Hepatitis C
Interventions: Daclatasvir, Sofosbuvir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 37
States / cities: Birmingham, Alabama • Beverly Hills, California • Long Beach, California + 27 more

Conditions: HIV Infection
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV
Interventions: PRO 140; Biological
Lead sponsor: Drexel University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: Stanford, California • Denver, Colorado • St Louis, Missouri + 3 more

Conditions: Syphilis
Interventions: Benzathine Penicillin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 10
States / cities: Birmingham, Alabama • Atlanta, Georgia • Indianapolis, Indiana + 7 more

Conditions: HIV-1 Infection
Interventions: DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to DOR/ISL; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 599 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 17
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 14 more

Conditions: Human Immunodeficiency Virus
Interventions: IMB, Information-Only Control; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 17 Years to 24 Years · Male only
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: HIV Infections
Interventions: apricitabine; Drug
Lead sponsor: Avexa; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: Dolutegravir (DTG), Lamivudine (3TC), Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 719 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 15
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Ft. Pierce, Florida + 12 more

Conditions: Lymphoma, Nonneoplastic Condition
Interventions: polymerase chain reaction, laboratory biomarker analysis; Genetic · Other
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 16
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 11 more

Conditions: HIV Infections
Interventions: Nystatin, Didanosine; Drug
Lead sponsor: Argus Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2008
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 1,300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2013
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Diego, California

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 482 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 28
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 14 more

Conditions: HIV, Hepatitis C, Co-Infection
Interventions: Prep-C, Educational Control; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 21 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Infection, Human Immunodeficiency Virus
Interventions: BMS-663068, Methadone, Buprenorphine and Norbuprenorphine; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 2
States / cities: Orlando, Florida • Overland Park, Kansas

Search by objective public record fields.

Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen

Long-Term Effects of HIV Exposure and Infection in Children

A Study of Itraconazole in the Prevention of Histoplasmosis, a Fungal Infection, in HIV-Infected Patients

Development of Serologic Assays for Human Herpes Virus-8

CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)

Mitochondria in HIV and Aging (MITO+)

Contribution of Dolutegravir to Obesity and Cardiovascular Disease

Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection

A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.

Investigation of The Effect of Cenicriviroc (CVC) Plus FTC/TDF on Cardiovascular Disease Risk Factors

PRO 140 for Human Immunodeficiency Virus Infection

Phase 4 Comparative Trial of Benzathine Penicillin G for Treatment of Early Syphilis in Subjects With or Without HIV Infection

Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)

Mobile-health (mHealth) Intervention to Support HIV Self-testing and PrEP Uptake Among Young Men Who Have Sex With Men

A Study to Investigate the Cardiovascular Safety of Apricitabine in Healthy Subjects

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma

A Study of Nystatin in HIV-Infected Patients

A Test of Behavioral Intervention for Women at High Risk for HIV Infection

Acute HIV Infection Observational Study

Observing Patients With Early HIV Infection

A Multi-Center Clinical Trial To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients With AIDS Post First Episode PCP

Intervention to Improve HCV Treatment Uptake and Adherence in HIV/HCV Coinfection

A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone